Skip to main content
. 2015 Dec 14;7(4):4584–4597. doi: 10.18632/oncotarget.6612

Figure 4. Prognostic value of EZH2 high expression in patients with breast, lung or colorectal cancer.

Figure 4

A. meta-analysis of EZH2 high expression and overall survival in patients with breast cancer; B. meta-analysis of EZH2 high expression and overall survival in patients with lung cancer; C. meta-analysis of EZH2 high expression and overall survival in patients with colorectal cancer; D. meta-analysis of EZH2 high expression and disease free survival in patients with breast cancer; E. meta-analysis of EZH2 high expression and disease free survival in patients with lung cancer; F. meta-analysis of EZH2 high expression and disease free survival in patients with colorectal cancer;